All News

⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
swethaann23 swethaann23 ( View Tweet)
What's Cool and Hot in Vasculitis: Dr. Janet Pope reviews abstracts #0505, #0466, #0430, #0507 and #0504, being presented at the #ACR21 annual meeting. https://t.co/7XwjFuJEMM https://t.co/BC9wjPzNC0

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting. https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI

Links:

Dr. John Cush RheumNow ( View Tweet)
Abst 1517 Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE - Most common rheumatic IRAE = inflammatory arthritis - Higher prevalence of ANA in those tx w/ chemo prior to ICI #ACR21 @RheumNow https://t.co/7qgogSMjUr
Akhil Sood MD AkhilSoodMD ( View Tweet)
Put those two RF together (essentially nailing down RA pts at risk of cancer): age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30) age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24) neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55) #ACR21 @RheumNow https://t.co/Uvr4wBhFVF
David Liew drdavidliew ( View Tweet)
So I guess you can look at this as you want: Arguably, if you are <65 & a never smoker, then maybe the risk isn't there. Once you start adding risk - maybe this is something we need to be having hard conversations with pts about. Plenty to think about here... #ACR21 @RheumNow

David Liew drdavidliew ( View Tweet)

There will be plenty of debate about ORAL Surveillance, as there should be. We will see more granular data, as we should. Whatever the case, it's hard to argue that there's no cancer risk with tofacitinib vs TNFi in RA, at least for some patients at higher risk. #ACR21 @RheumNow

David Liew drdavidliew ( View Tweet)

#ACR21 Ab#1942. RABBIT: Non-melanomatous skin ca on DMARD Multivariable analysis: 👉Adjusted HR for Abatacept HR ~2 Risk of co-medication with MTX needs further investigation https://t.co/JOKNyYVZfX @Rheumnow https://t.co/DyG5hbOc8Z

Links:

Eric Dein ericdeinmd ( View Tweet)
#Abatacept gives more skin cancers in #RheumatoidArthritis from RABBIT registry? pts in Abatacept had more comorbidity? Channeling bias. Who knows. Abst#1942 #ACR21 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Wanna know more about the relation between 🌦🌩 and RA disease activity? It's below 👇🏻 https://t.co/oUC7lrTEwF #Abst1912 #ACR21 @RheumNow https://t.co/3iJra047gC

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
COREVITAS registry 600+ PsA/SpA pts 7yrs follow-up TNFi ❗️Overall low persistency 39% at 2 yrs ❕TNFi persistency = across 6 disease domains ❗️Shorter treatment duration if Enthesitis or Ax PsA #ACR21 #Abst1818 @RheumNow https://t.co/1aE8eWn4TD
Aurelie Najm AurelieRheumo ( View Tweet)
NOR-DRUM B: infliximab therapeutic drug monitoring (TDM) vs standard of care (SoC) Goal inflix. level 3.0-8.0mg/L 🔹axSpA, PsA, PsO, RA, UC, Crohns 🔹Dose⬆️or⬇️based on how level & +/- inflix-Ab 🔹Proactive TDM superior https://t.co/BHQwJSVHxD #ACR21 Abst#1946 @RheumNow #ACRBest

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Oh, also VTEs. Not designed to do this, but: - We don't use 10mg bid & we shouldn't start - 5mg bid looks just fine - In fact, in patients with a VTE history, 5mg bid is numerically similar (?better) to TNFi Somehow, VTE in tofa is an overshadowed non-event! #ACR21 @RheumNow https://t.co/fvMSg49kk6
David Liew drdavidliew ( View Tweet)
So today the full NOR-DRUM B details - the first positive RCT for TNFi TDM in rheum HR 2.09 for worsening with standard care (clinician discretion) vs proactive TDM (change before clinical issue) Open label, but this is a lot better than guessing! #ACR21 ABST1946 @RheumNow https://t.co/kyKh00ARVW https://t.co/uW6vYHLI7Y

Links:

David Liew drdavidliew ( View Tweet)
Different drugs may target different pathways in PsA! S-cell proteomic biomarkers in SELECT-1 PsA study: 💥UPA targets ▶️ Adaptive immunity, bone metabolism pathways 💥ADA targets ▶️ innate immunity pathways. Paving the ground for personalised therapy? #ACR21 #Abst1816 @RheumNow https://t.co/hyMP4PtUnM
Aurelie Najm AurelieRheumo ( View Tweet)
An artificial neural network for detection of radiographic #sacroiliitis in axSpA? @DrPoddubnyy 📌Specificity - 93.9% 📌Sensitivity - 78.7% Potential tool for interpreting SIJ in nonspecialized ctrs or clinical trials This is a game changer!🤓 @RheumNow #ACR21 #ACRBest abs1919 https://t.co/2li0dNWtLc
sheila RHEUMarampa ( View Tweet)
And it’s a wrap!! Time for a pool game🎱 Delighted to have been reporting for @RheumNow alongside an amazing faculty! and delighted to have been able to be around amazing colleagues to attend #ACR21 convergence! See you all next year, hopefully for real! 🤞🏼 https://t.co/JBoKd7zNvl
Aurelie Najm AurelieRheumo ( View Tweet)
Abstr 1677 Miwa & colleagues studied the effect of bDMARDs on cholesterol levels in RA patients - bDMARDs may affect HDL levels - no significant effect was seen on LDL #ACR21 @RheumNow https://t.co/yb35HMDlxN
Akhil Sood MD AkhilSoodMD ( View Tweet)
Bridging the gap in the delayed diagnosis of axSpA Dr. Swetha Ann Alexander ( @swethaann23 ) shares the findings from several abstracts presented at #ACR21. https://t.co/8eEXIbyopA https://t.co/brtaZztRhl

Links:

Dr. John Cush RheumNow ( View Tweet)
×